Ann: Partnered Program Update, page-39

from what I can ascertain don’t be surprised if Spl try and get the AZD0466 for an internal trial

I sincerely hope you are wrong in relation to AZD0466 @majestic001 ... it would be reckless IMO in the company's current financial position. Let's face it they recently pulled the DEP® gemcitabine phase 1/2 trial to conserve expenditure so to then go out and undertake an AZD0466 trial instead ??

If AstraZeneca want to sign over the AZD0466 IP to Starpharma at no charge then sure take it but I wouldn't be starting another trial until we see some serious DEP® licensing deals / $$.

As for being right .... I wish I wasn't - to see your portfolio lose another $100k in just one day due to this mob kinda makes me wish I was wrong but hey let's see whether the Viraleze UK after market study shows the results I expect as that could turn the company around IF JF & Co. can secure a global pharma distribution deal / royalty deal off the back of it